Respiratory
During the course of a normal day, humans breathe nearly 25,000 times. Respiratory diseases range from mild and self-limiting such as the common cold to life-threatening such as bacterial pneumonia or pulmonary embolism. |
They are a common and prevalent cause of illness and death that affect millions of people worldwide. If all types of lung disease are lumped together, it is the number three killer in the United States. Our Respiratory group is a dedicated clinical operations team with years of experience working on global trials across this diverse spectrum of indications in both adult and pediatric populations.
With our therapeutic and regulatory expertise, we can provide strategic thinking and full clinical plan development that considers the scientific rigor of a specific program. We deploy specialized recruitment and retention strategies that have proven success in respiratory trials across multiple indications including:
- Asthma
- COPD
- Cystic fibrosis
- Lower respiratory tract infections
- Lung cancer
- Pulmonary arterial hypertension
- Smoking cessation
- Upper respiratory tract infections
For more information on INC Research’s therapeutic expertise in Respiratory, click here.
|
Case Studies
Respiratory: Adult Asthma Program
Respiratory: Allergic Rhinitis Program
Respiratory: Phase 1 Pediatric Asthma Study
|
|
